Abstract Little is known about the experiences of women with Fabry disease. The aim of this study was to explore women's experiences of being heterozygous for Fabry disease. We used an explorative qualitative study design and selected ten Norwegian women who were known heterozygous for Fabry disease to participate. We conducted in-depth semi-structured interviews and analyzed the interviews using inductive thematic analysis. We found that learning about one's heterozygous status may be devastating for some. However, for most of the participants, heterozygous status, as well as doctors' acceptance of symptoms in women heterozygous for Fabry disease, provided an explanation and relief. Although many women did not consider themselves ill, they wished to be acknowledged as more than Bjust carriers.^The participants were grateful for enzyme replacement therapy, although it had its burdens regarding time, planning, and absences from school or work. Women with Fabry disease felt that the lack of knowledge among healthcare professionals about Fabry disease was frustrating and worrisome. These findings suggest that healthcare professionals should acknowledge the different ways women react to their diagnosis, and be aware of the personal costs of receiving treatment.
Introduction
Fabry disease (OMIM#301,500) is a rare X-linked disorder caused by a mutation in the GLA gene. The true carrier frequency is unknown, but data from newborn screening indicate an incidence rate (boys and girls) around 1:3000-1:4000 (Inoue et al. 2013; Mechtler et al. 2012; Spada et al. 2006) . The GLA mutation causes a deficient activity of the enzyme alpha-galactosidase and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form of Fabry disease is characterized by periodic crisis of severe pain in the extremities, the appearance of vascular cutaneous lesions (angiokeratomas), hypohidrosis, characteristic corneal and lenticular opacities, and proteinuria (Germain 2010) . End-stage renal disease, cardiovascular and/or cerebrovascular disease typically occur in the third and fourth decades of patients' lives. Once the diagnosis is made, symptoms of Fabry disease can be effectively and safely treated with enzyme replacement therapy (ERT) (Schiffmann et al. 2001) . Patients with Fabry disease report a lower quality of life (QoL) compared to the general population, but the effect of ERT on QoL is unknown (Arends et al. 2015) . Diagnosing and caring for persons with Fabry disease require a multidisiplinary approach (Laney et al. 2013) .
Women that are heterozygous for Fabry disease commonly manifest symptoms (Guffon 2003; Wang et al. 2007 ), but the phenotype in women is more varied than in men (Wilcox et al. 2008) . Women with Fabry disease describe negative experiences with healthcare professionals related to their gender, carrier status and the rarity of the disease (Gibas et al. 2008) . Researchers have reported that women with Fabry disease have a significant burden of disease and impaired QoL (Wang et al. 2007; Wilcox et al. 2008) . In a study of four Canadian women with Fabry disease, all had feelings of guilt for passing on Fabry disease to their sons (Sadek et al. 2004) . Women that are heterozygous for Fabry disease may have symptoms and should therefore not be called carriers (Wang et al. 2007) . Women with Fabry disease also have a 50 % risk of passing the mutated GLA gene to their offspring.
Earlier published literature on carriers of genetic disorders may therefore be relevant for understanding a portion of women's experiences. Previous studies on carriers of genetic disorders have focused primarily on the process of carrier testing and less on the experience of being a heterozygous female. Studies show that carrier testing has an effect on reproductive decision making (Lewis et al. 2012) , including the sadness of relinquishing expectations of having children (Williams and Schutte 1997) . Women who pass on an Xlinked genetic condition have feelings of responsibility (for informing others of the diagnosis) (Kay and Kingston 2002) , guilt, and stigmatization, and feel blamed by their child's father (James et al. 2006) . Finnish patients with X-linked Alport syndrome, and their family members, found the lack of knowledge about the diagnosis among healthcare professionals problematic and stressful (Pajari and Sinkkonen 2000) . Communicating about the genetic diagnosis in the family was also difficult. Williams and Schutte found that communicating results from genetic testing to family members was difficult (Williams and Schutte 1997) .
Purpose of the Study
In genetic diseases, health may be viewed not only as a personal responsibility but also as a moral issue across generations (Hallowell 1999) . In Hallowell's study on women who received genetic counseling for hereditary breast/ovarian cancer (Hallowell 1999 ) the women constructed themselves as selves-in-relation to others and felt responsible for their kin (past, present, and future generations). There is little research on women's experiences of being heterozygous for Fabry disease. The aim of the study was to expand knowledge about women with rare X-linked disorders, specifically Fabry disease, in order to provide the appropriate healthcare and support. Major research questions were: What psychosocial issues do women that are heterozygous for Fabry disease experience? How do they view their status, and how do they experience encounters with the health professionals?
Methods

Design
We used an exploratory qualitative research approach, specifically in-depth interviews to gather insights into the women's experiences.
Sample and Recruitment
A nurse at the national competence centre for Fabry disease, Centre for Rare Disorders, Oslo University Hospital, Norway invited women known to be heterozygous for Fabry disease to participate in the project. The Centre for Rare Disorders is an interdisciplinary competence centre, providing information, counselling, support, and seminars for approximately 70 rare disorders. There is no register for Fabry disease in Norway, thus there is no national record of symptomatic or nonsymptomatic heterozygous women. The Centre for Rare Disorders has a voluntary registry of patients who contact the centre. The original intended sample was 10 women heterozygous for Fabry disease with affected children. The principal investigator began recruitment amongst her own clinical population of 14 possible participants and recruitment was expanded via a mailing through the Norwegian Fabry patient support group. The exact number of invited women is unknown, as we did not ask the patient support group to report that number. Despite several mailings and follow-up, response was poor. Inclusion criteria were revised to include all women heterozygous for Fabry disease. The ten women who accepted the invitation were all ethnic Norwegian and aged 24-77 years (mean = 54). For additional details on clinical and demographic characteristics, see Table 1 .
The principal investigator contacted the participants by phone to complete the informed consent process providing information about the project, ethical considerations, and the plans for publication. The participants signed and returned a consent form sent to them by mail and they scheduled their interview time and location.
Data Collection
The principal investigator conducted all 10 interviews, which were semi-structured and conducted on the university hospital premises or at participants' homes between February 2013 and March 2014. The interviewer informed the participants that she was a clinical geneticist and researcher and that her role in the project was as a researcher. The interviews lasted on average 60 min (Range: 40 to 75 min) and were digitally recorded and transcribed verbatim. We used an interview guide with five open questions concerning what it was like finding out about the diagnosis, experiences of being heterozygous for Fabry disease, thoughts about having a child with the disorder, communicating about genetic disorders in the family, and the women's experiences with the healthcare system. The interview guide was informed by previous literature and was developed by the research team, with input from professionals who had experience with managing Fabry disease.
Data Analysis
We adopted an inductive thematic analytical approach for analyzing the interviews (Braun and Clarke 2006) . The principal investigator listened to the interviews and read the transcripts several times, and wrote a short summery for each interview to get an overall impression of the women's experiences. The second and fourth authors read transcripts, while the third author joined in after the themes had been identified. The principal investigator coded all the material by using a software program (Hesse-Biber et al. 1991) , and the coding process was done in tandem with the last author and discussed with all the authors. We then grouped the codes into sub-themes and themes. We chose main themes and collected extracts of data coded in relation to the themes. We reviewed the themes and data extracts by going back to the transcripts and to the research questions. In writing this article, we analyzed the candidate themes further and assigned each participant a number. The Norwegian authors translated the quotes from the interviews.
Ethical Approval
We obtained ethical approval for the study, before and after changing the inclusion criteria, from the Regional Committee 
Results
We identified three main themes in the analysis: learning about being heterozygous for Fabry disease, coping with Fabry disease, and experiences with follow-up and treatment.
Learning About Being Heterozygous for Fabry Disease
Most participants had learned about their diagnosis as adults after a father, brother, son, or daughter had been diagnosed with Fabry disease. Even though some women had experienced symptoms for many years, some since childhood, they reported that no one had thought about Fabry disease, and they shared stories about not being understood or not being taken seriously about their symptoms. Thus, being diagnosed with Fabry disease, and having symptoms related to this status recognized by doctors, represented a major change in how the women looked at themselves and how health professionals and others understood their symptoms:
Before, everyone managed everything and I didn't manage a thing, and what I heard was that I was lazy or didn't care. But, finally, they believed me, and then everything fell into place. It was good to get a diagnosis. It verified that I was not crazy…The pieces in the puzzle fell into place. (participant 9)
Other women also reported the relief of getting an explanation, not only for their present symptoms but also for previously unexplained symptoms. Not all participants shared this feeling of relief however, participant 2 stated:
And then my world fell apart, with that carrier diagnosis because I became someone who was ill. Maybe mostly This participant did not have any symptoms and had trouble accepting her Fabry diagnosis. She experienced a great shock when she found out. She was started on enzyme replacement therapy before she had any symptoms, which resulted in conflicting emotions, as she was both happy and grateful for treatment. However, as this process also labeled her as Bill,^she felt her Bworld fell apart.Â nother participant stated that, regardless of having some symptoms, she preferred to see herself as a carrier instead of as a patient because she wanted to think of herself as healthy. This was also important to her because she saw that her son and other men with Fabry disease had more symptoms than she did. Thus, compared to them, she did not define herself as ill. Yet she said she felt vulnerable and claimed that if the doctors defined her as Bjust a carrier^they would not treat her appropriately. Following this line of reasoning, she added that when she has pain in her chest the doctors should take that seriously. As she stated Beven carriers may have symptoms^:
I mean, if I look at myself as healthy, it kinds of eases it in a way, right? Then I am not ill, right, just a carrier. So, in a way it is positive, but at the same time, it does not feel good when others say that I am just a carrier. (participant 3)
Most participants described challenges in communicating about the genetic disorder with their family members, although they thought it was very important to be open about the condition, especially those who had experienced concealment of information about the genetic disease. Participant 4 had for many years known her father was ill, but she did not know he had Fabry disease until she was adult. It was very important for her to be open about Fabry disease with her children:
I did not think much about why my parents did not talk about it [Fabry disease]. I just decided that my children should know.
Some participants experienced that different opinions about Fabry disease in the family constrained an open dialogue about the condition. Other women found that their children did not want to talk about the disease because they wanted their friends and others to know them as healthy and avoid focusing on the disease and the treatment. One participant had had a very ill father, and her family had been concerned with her father's illness instead of communicating about the genetic aspect of the disease. Social stigma associated with the genetic condition was another reason for the lack of communication. Participant 1 said sadly:
They [the children] do not want to talk about Fabry disease. They want to hide it. They say: BDon't tell anybody about it. Don't say you get medication. Don't say it, do not say anything.^I do not like all this hiding.
However, participant 6 discussed the stigma matter-offactly:
I guess it is a bit like that with genetic disorders, it is a bit stigmatic and shameful, right, so you cannot [talk about it].
Another distinct theme running through the interviews was the experience of feeling guilty for having passed on a Bfaulty gene^to children and grandchildren. For example, the feeling of relief the women experienced when a child or grandchild did not inherit the mutated gene was overwhelming. Two participants, however, did not feel guilty as they felt there was nothing they could have done about it; it was just the way it was, as described by participant 7.
I think it is very sad [that her daughter inherited the mutation]. I think it is sad, but I don't feel guilty, because I did not know about the mutation. I can't feel guilty for something I cannot help. (participant 7)
Another participant did not believe she had feelings of guilt but had some thoughts about why this was the case:
Maybe I don't want to. It is possible that I cannot bear to think about it in regards to my child. If it [feeling of guilt] is there, it is very well hidden, and so it shall continue to be. (participant 2)
Coping with Fabry Disease
Even if a diagnosis served as an explanation for many years of Bunease,^it was important for all the women to make a distinction between Fabry disease and their daily life. Some women commented that seeing the doctor regularly interfered with their life, and emphasized that if they worked from 8 a.m. to 4 p.m., it was almost impossible to get a follow up appointment outside regular work hours. Not wanting colleagues to know about the disease, and not wanting to draw attention to the diagnosis made one woman choose to take unpaid leave from work to have her enzyme replacement treatment. She then received the treatment Bsecretly^and did not have to fill in forms or request time off from work. Even though she felt it was not an ideal way of dealing with the situation, it was the only way she could cope. To separate social life and one's social identity from the disease was something with which the participants were quite intensively occupied:
I do not use my disease in a social setting, I don't use it, I am very conscious about that. It is not like I'm Mrs. Fabry, I am more than that. (participant 6) One participant said that she had to mentally compartmentalize the particularly bad episodes, when she experienced her worst symptoms, from the Brest of her life^or else she would get depressed and consider herself as someone with Ba disease.^Even participants with the most severe symptoms emphasized how much effort they put into not being seen as someone with an illness:
It is a very small part of life and you will probably not get a better life spending two hours a day preparing for everything that may happen. Yes and, when I am with friends it has nothing to do with Fabry. Most of what I do has nothing to do with Fabry. So really, if I was to draw a sector diagram of myself, Fabry would get a really small part of it. (participant 8)
Experiences with Follow-Up and Treatment
Although participants were grateful to live in Norway, a country where they could receive the treatment they needed, it was not without personal cost. Several participants discussed the time consuming nature of hospital appointments, planning to get the medication from the pharmacy, planning treatment time, planning how to get someone to help them insert the cannula and having to take absences from school or work.
Participant 5 observed:
It is just that, everything must be planned. Therefore, a disease that requires so much treatment, and a healthy lifestyle to prevent you from becoming ill, involves planning. Rigorous planning: Pharmacy, GP, hospital, prescriptions and all that. It all takes a lot of time, actually. So, it takes a lot of my leisure time to plan and to pick up things. And you need to store things a certain way and I need a lot of equipment, IV [intravenous] equipment.
Participant 5 also felt the healthcare system expected her to be grateful for receiving the treatment. She worked in the healthcare system herself, and she felt pressured to make all of the arrangements regarding her own treatment. When inserting the cannula turned out to be a problem for her, she felt useless and was happy when she found someone to help her with the procedure:
Then I have this specialist nurse at the hospital I can call. ….. She is like BYou just get here, and we will put a cannula in, of course we will.^And that saves my day, and my week. It is that one practical problem that destroys it for me. If I have a cannula I can manage myself. It is such a small thing that makes everything not work. And you feel, you feel bad because you criticize the healthcare system a lot. (participant 5) Some women felt that receiving treatment changed their own self-perceptions and the way others valued them. One participant stated that her grandchildren, whom she believed had symptoms of Fabry disease, had told her they did not want treatment as they did not want the insurance company to know about Fabry disease. Another participant mentioned she had not told her coworkers she had Fabry disease, as she was afraid of being discriminated against.
Commonly the women experienced deep frustration regarding the lack of health care providers' knowledge of Fabry disease:
Nobody knows anything about the diagnosis. Nobody has heard about it. It could just as well have been a new chocolate or ice cream in the store. (participant 9)
Participants stated that when doctors did not know about the symptoms of Fabry disease, it made the women feel insecure, misunderstood, afraid and sometimes angry. One participant, however, felt her doctor attributed all her symptoms to Fabry disease and this made her frustrated:
My doctor puts everything [all her symptoms] on Fabry, but everything is not Fabry! (participant 10)
Discussion
Coping with the Diagnosis
The study showed that women who learn that they are heterozygous for Fabry disease may experience relief, distress or both. This finding resonates well with the work of Bury (1982) and Charmaz (1983) , who showed that a lot is at stake when one's identity as a healthy person is being challenged by a diagnosis and treatment for a chronic disorder. For women with symptoms, the diagnosis explained lifelong problems.
Living with pain and fatigue without having an explanation, and feeling like a hypochondriac, had been significant burdens for many of the participants. In a study of women with Fabry disease by Street et al. (Street et al. 2006 ) the majority of the women reported diffuse symptoms such as fatigue, pain and gastric problems. The women reported a significant lower health-related quality of life compared to healthy women. Symptoms of the disease may be one of several reason for the lower quality of life.
While for some women in our study the diagnosis of Fabry disease in itself was seen as stigmatizing, it was however more stigmatizing to have diffuse and unexplainable symptoms. A possible reason is that women with diffuse symptoms may be at risk of being put in the same category as women diagnosed with fibromyalgia or myalgic encephalopathy (ME) (Album and Westin 2008 ). Yet, as visibility, according to Goffman (1963) , is the prime marker of stigma, it is likely that stigmatization related to Fabry disease is not experienced as strongly as it might be for other diagnoses (Dures et al. 2011) . Nonetheless, the treatment process with cannula insertion and IV infusions is very visible for other people and was something participants found stigmatizing.
Several of the participants made an effort to separate the disease from their Bdaily life.^As one participant stated BIt's not like I am Mrs. Fabry, I am more than that.^This statement emphasizes that women with Fabry disease do not find it necessary or helpful to identify strongly with their diagnosis. Their thoughts reflect their embedded role within a culture in which people with rare diagnoses or chronic illness may be suspected of using their diagnoses to obtain secondary gains.
We found that our participants experienced difficulties with communicating about Fabry disease within their family, which is in line with previous research on other genetic disorders (Forrest et al. 2003) . The findings emphasize the need for increased genetic counseling support to families with rare genetic conditions (Forrest et al. 2008 ). Identifying at-risk family members by a detailed pedigree is important (Laney and Fernhoff 2008) . Women have different ways of coping with the information about being heterozygous for Fabry disease and coping with the disease. Health professionals may provide more individually tailored care and support if they recognize the different methods of coping with the condition. Finally getting an explanation, not just for the women, but also their relatives, friends and colleagues, was very important. This fits well with van Manen's (1998) description of how explaining can have a healing effect, and supports the theory that meaning-making may help genetic counselors to guide patients and families to adapt to rare disorders (Helm 2015) .
Feelings of Guilt
Feelings of shame about having vague and unexplainable symptoms may be alleviated when a diagnosis explains symptoms, but a genetic diagnosis raises new issues. Previous research on familial hypercholesterolemia showed that sufferers experienced guilt and shame for not following the diet, but not for having an inherited diagnosis (Frich et al. 2007) . We found that almost all the participants in the current study reported negative feelings about passing on the mutation for Fabry disease to children. The findings indicate that a difficult part of having Fabry disease is the risk of passing the mutation on to later generations. In Bury's (1982) description of chronic illness as a biographical disruption, in which expectations and plans for the future must be reexamined, children and grandchildren are also important to consider. Genetic counselors and other health professionals must be aware of the different aspects of learning about one's status as a women with Fabry disease. Discussing challenges related to communicating about Fabry disease in the family should be a priority.
Receiving Enzyme Replacement Treatment
The findings of this study suggest that although women were grateful for the available treatment, the enzyme replacement therapy had personal costs in terms of the time required for planning and absences from school or work. Treatment for Fabry disease is administered as intravenous enzyme replacement therapy once every two weeks. As treatment is not required every day, it may be easy to isolate one's engagement with one's disease from the rest of one's life, and not allow it play too large a role in one's lives. Not disclosing one's Fabry status to other people, such as colleagues at work, also seemed to be an important issue for participants in our study. Norwegians view close friendship as important to their health (Gele and Harslof 2010) , and it is thus surprising that some of our participants concealed the disease from their closest relations. The fact that the disease is inherited may counteract the general norm in Norway of sharing diagnoses and illness experiences with family and friends. Fabry disease is a rare disorder, and not well known by health professionals and the public. This may contribute to the desire to separate one's daily life from the disease. It is an extra burden for people with chronic disorders to have a rare disorder (Jaeger et al. 2015; Wallenius et al. 2009 ). The participants in this study made a conscious choice and effort to separate the disease from daily life. For some, this was hard work. It may be easy to hide a diagnosis as Fabry disease, even when receiving enzyme replacement therapy, but hardly possible to separate from one's sense of self (Van Manen 1998) . The need to separate the disease from one's self found in the study has been described for other diseases such as diabetes and rheumatoid arthritis (Stamm et al. 2009; Tilden et al. 2005) . Even though patients are grateful for the option of receiving expensive treatment, healthcare professionals should be aware that treatment may have personal costs.
Study Limitations and Strengths
As it is voluntary to join the patient registry at the centre, the women who were recruited may represent a group with more symptoms of, and issues with, Fabry disease than heterozygous women not registered at the centre. Recruitment was difficult. Reasons for not responding may be that some women find it difficult to talk about issues regarding being heterozygous for Fabry disease, they did not have time, and/or or they did not find it important. Yet, in order to obtain the desired number of participants we had aimed for, we had to change the inclusion criteria and include women with healthy children, and women without children. In sum, we recruited a sample with varied age and with different experiences with Fabry disease. Some had symptoms and received treatment, and some participants did not have symptoms. The change in inclusion criteria may have resulted in a broader variety in the group and thereby may also be a strength of the study. We believe the group represented different aspects of Fabry disease, and our aim was to obtain deeper insight into the women's experiences. Four researchers with different backgrounds in healthcare and social science were involved in analyzing the data, which we consider a methodological strength. A positive aspect of the interviewer being familiar with genetics and being a doctor was her previous experience counseling carriers and people in crisis, which enabled knowledge of the disease and greater empathy. However, knowledge of the medical conditions and genetic aspects may hinder the interviewer's openness to a wide range of perspectives. The participants' expectations of what a doctor, or even a female researcher, wants to hear may hinder the participant in talking about certain understandings and experiences.
Practice Implications
This study showed that in order to understand how women experience Fabry disease, and thereby make a more personalized approach to genetic counseling, it is very important to listen to women's narratives. The findings indicate that health professionals should acknowledge individual variations in how heterozygous females experience and reflect on Fabry disease as a disorder. Although finding relief in being diagnosed is quite common, a distinct wish for separating the diagnosis from oneself as a person was also often mentioned. Additionally, health professionals should be aware of feelings of guilt to which the diagnosis might give rise. Consequently, women with Fabry disease often need support concerning communication about the condition in the family as well as the individual and psychosocial costs of receiving enzyme replacement therapy. Further, the study supports published literature and information from lay organizations such as the Fabry Community that women heterozygous for Fabry disease should not be called carriers (Wang et al. 2007 ; Bhttps://www.fabrycommunity.com/en/Patients/Education/ Women.aspxB).
Research Recommendations
More qualitative research on the psychological impact of receiving a diagnosis of Fabry disease, and the personal costs on receiving enzyme replacement therapy, may provide a better understanding of how the women view their diagnosis and the impact of living with it. A survey of psychosocial wellbeing could offer insights into these phenomena, complementary to qualitative studies.
Conclusions
Women who are heterozygous for Fabry disease react to and reflect on their diagnosis differently, and genetic counselors and health professionals should provide personalized information, support, and management. Genetic counselors and other health professionals should be aware of and acknowledge feelings of guilt, difficulties in communicating within the family, and the personal costs of receiving treatment, and support the patients on these issues.
